Multiplicity Testing Procedure Selection in Clinical Trials Rachael Wen Ph.D JSM 2018 of 8.

Slides:



Advertisements
Similar presentations
Emerging Issues with Adaptation of Clinical Trial Design in Drug Development* H.M. James Hung Division of Biometrics I, Office of Biostatistics, OPaSS,
Advertisements

Gatekeeping Testing Strategies in Clinical Trials Alex Dmitrienko, Ph.D. Eli Lilly and Company FDA/Industry Statistics Workshop September 2004.
Lesson #24 Multiple Comparisons. When doing ANOVA, suppose we reject H 0 :  1 =  2 =  3 = … =  k Next, we want to know which means differ. This does.
1 Health Warning! All may not be what it seems! These examples demonstrate both the importance of graphing data before analysing it and the effect of outliers.
Statistical Modeling and Data Analysis Given a data set, first question a statistician ask is, “What is the statistical model to this data?” We then characterize.
1 O Guilbaud, MCP2007, July 8-11, Vienna, v.1 Simultaneous Confidence Regions corresponding to Holm’s Step-down MTP (and other CTPs) Olivier Guilbaud.
By Trusha Patel and Sirisha Davuluri. “An efficient method for accommodating potentially underpowered primary endpoints” ◦ By Jianjun (David) Li and Devan.
A new group-sequential phase II/III clinical trial design Nigel Stallard and Tim Friede Warwick Medical School, University of Warwick, UK
1 An Overview of Multiple Testing Procedures for Categorical Data Joe Heyse IMPACT Conference November 20, 2014.
Design and analysis of clinical trials MULTIPLE COMPARISONS.
The Closure Principle Revisited Dror Rom Prosoft Clinical IMPACT Symposium November 20, 2014 Contributions by Chen Chen.
Hypothesis Testing Steps of a Statistical Significance Test. 1. Assumptions Type of data, form of population, method of sampling, sample size.
Adaptive Designs for Clinical Trials
Multiple Testing Procedures Examples and Software Implementation.
Carl-Fredrik Burman, PhD, Assoc Prof Senior Principal Scientist AstraZeneca R&D Mölndal Multiplicity in a decision-making context.
Luveris ® New Drug Application ( ) Kate Meaker, M.S. Statistical Reviewer Division of Biometrics II Kate Meaker, M.S. Statistical Reviewer Division.
Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 1 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Alpha Recycling in Confirmatory.
Activity #3 Testing Medicines: A Clinical Trial. Key Words Clinical Trial – a test performed on volunteers, typically to test medicines, before the products.
Testing and Estimation Procedures in Multi-Armed Designs with Treatment Selection Gernot Wassmer, PhD Institut für Medizinische Statistik, Informatik und.
The Role of Statistical Methodology in Clinical Research – Shaping and Influencing Decision Making Frank Bretz Global Head – Statistical Methodology, Novartis.
Ferring Pharmaceuticals The extended Williams’ trend test - Background and practical example Anders Malmberg DSBS Generalforsamling May 26th, 2011.
Institut für Medizinische Biometrie, Epidemiologie und Informatik Aesthetics and power in multiple testing – a contradiction? MCP 2007, Vienna Gerhard.
Scientific Method for a controlled experiment. Observation Previous data Previous results Previous conclusions.
False Discovery Rates for Discrete Data Joseph F. Heyse Merck Research Laboratories Graybill Conference June 13, 2008.
Adaptive Designs for U-shaped ( Umbrella) Dose-Response Yevgen Tymofyeyev Merck & Co. Inc September 12, 2008.
1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.
All-or-None procedure: An outline Nanayaw Gyadu-Ankama Shoubhik Mondal Steven Cheng.
DSBS Discussion: Multiple Testing 28 May 2009 Discussion on Multiple Testing Prepared and presented by Lars Endahl.
A Comparison of Some Methods for Detection of Safety Signals in Randomised Controlled Clinical Trials Raymond Carragher Project Supervisors: Prof. Chris.
How to Read Scientific Journal Articles
1 Statistics in Research & Things to Consider for Your Proposal May 2, 2007.
1 Statistical Significance Testing. 2 The purpose of Statistical Significance Testing The purpose of Statistical Significance Testing is to answer the.
Elementary statistics for foresters Lecture 5 Socrates/Erasmus WAU Spring semester 2005/2006.
The Multiple Comparisons Problem in IES Impact Evaluations: Guidelines and Applications Peter Z. Schochet and John Deke June 2009, IES Research Conference.
The Nature of Science & Science Skills Test Review.
Bayesian Approach For Clinical Trials Mark Chang, Ph.D. Executive Director Biostatistics and Data management AMAG Pharmaceuticals Inc.
Power & Sample Size Dr. Andrea Benedetti. Plan  Review of hypothesis testing  Power and sample size Basic concepts Formulae for common study designs.
1 Chihiro HIROTSU Meisei (明星) University Estimating the dose response pattern via multiple decision processes.
Simulation Study for Longitudinal Data with Nonignorable Missing Data Rong Liu, PhD Candidate Dr. Ramakrishnan, Advisor Department of Biostatistics Virginia.
Sample Size Determination
Guidelines for Multiple Testing in Impact Evaluations Peter Z. Schochet June 2008.
 (Worse) How to adjust multiple settings of the process parameters was outside of the knowledge of the engineers.  (Better) The engineers did not know.
Bonferroni adjustment Bonferroni adjustment (equally weighted) – Reject H 0j with p i
Frank Bretz (Novartis) U Penn – April 13, 2016 Acknowledgment: Willi Maurer, Paul Gallo (Novartis) Adaptive Designs: The Swiss Army Knife Among Clinical.
Posthoc Comparisons finding the differences. Statistical Significance What does a statistically significant F statistic, in a Oneway ANOVA, tell us? What.
The Scientific Method involves a series of steps that are used to investigate a natural occurrence.
A Parametrized Strategy of Gatekeeping, Keeping Untouched the Probability of Having at Least One Significant Result Analysis of Primary and Secondary Endpoints.
Sample Journal Club Your Name Here.
Sample Size Determination
Multiplication table. x
Multiple Endpoint Testing in Clinical Trials – Some Issues & Considerations Mohammad Huque, Ph.D. Division of Biometrics III/Office of Biostatistics/OPaSS/CDER/FDA.
Part Three. Data Analysis
THE SCIENTIFIC METHOD Science is a method to understand the constantly changing environment.
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Division of Biometrics III/Office of Biostatistics/OPaSS/CDER/FDA
DOSE SPACING IN EARLY DOSE RESPONSE CLINICAL TRIAL DESIGNS
[Presenter’s Name] [Presenter’s Group] [Date]
Czesław Domański Dariusz Parys University of Łódź Department of
Covering Principle to Address Multiplicity in Hypothesis Testing
JSM 2018 Practical Considerations on the Challenges to the Design and Analysis of Immuno-Oncology Trials Yabing Mai1, Yue Shentu2 1 AbbVie, Inc. 2 Merck.
Subhead Calibri 14pt, White
David Edwards and Jesper Madsen Novo Nordisk
Hui Quan, Yi Xu, Yixin Chen, Lei Gao and Xun Chen Sanofi June 28, 2019
Exact Inference for Adaptive Group Sequential Clinical Trials
Self-Designing Trials: Further Thoughts & Advances
Detecting Treatment by Biomarker Interaction with Binary Endpoints
Incorporating the sample correlation between two test statistics to adjust the critical points for the control of type-1 error Dror Rom and Jaclyn McTague.
Daniel Li and L.J. Wei Harvard University
Oncology Biostatistics
Presentation transcript:

Multiplicity Testing Procedure Selection in Clinical Trials Rachael Wen Ph.D JSM 2018 of 8

Background Multiple endpoints Repeated measurements 2/22/2011 Multiple endpoints Repeated measurements Correlations between hypotheses Hypotheses: Inherent clinical importance order Varied treatment effect sizes Case Study: Hypotheses: Primary: H1 and H2 Secondary: H3 and H4 Considerations: Clinical priority: H1>> H2 > H3> H4 Correlations: H1 and H2, H3 and H4 Individual marginal power: H3>>H2>(H1, H4) JSM 2018 of 8

Methods     Simes test Weighted Bonferroni test

Simulation Scenarios Graph 1 Graph 2 JSM2018 of 8

Simulation Results (Different MTPs) 2/22/2011

Simulation Results (How much power will gain?) 2/22/2011 Table: Power and power gain by alpha propagation in graphical approach Initial alpha Corr(H1,H2) H1 H2 H1* H2* (0.04, 0.01, 0, 0) -0.5 0.792 (2%) 0.833 (24.7%) 0.776 0.668 0.5 0.791 (1.9%) 0.799 (19.6%) (0.025, 0.025, 0, 0) 0.776 (8.8%) 0.843 (7.4%) 0.713 0.785 0.764 (7.2%) 0.831 (5.9%) (0.01, 0.04, 0, 0) 0.756 (29.9%) 0.852 (1.7%) 0.582 0.838 0.739 (27%) 0.851 (1.6%) Note: * power at initial assigned alpha level; Weighted closed parametric approach JSM 2018 of 8

Conclusions 2/22/2011 Hochberg and Hommel: reserved power, not flexible and Robust Graphical approach Attractive power, flexible and proper for complicate design with multiple endpoints with varied clinical importance and correlations Understandable and communicable to non-statistician Power gain extend depends on specific transition matrix, correlation between hypotheses, and marginal power of individual hypotheses ‘Optimal’ initial graph determined by exhaustive simulations JSM 2018 of 8

References: Bretz F., Mauer W., Brannath W., and Posch M., A graphical approach to sequentially rejective multiple test procedures. Statistics in Medicine (2009); 28: 586-604 Bretz F., Posch M., Glimm E., Klinglmueller F., Maurer W., and Rohmeyer K., Grphial approaches for multiple comparison procedures using Bonferroni, Simes, or parametric test. Biometrical Journal (2011); 6: 894-913 Hochberg, Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika (1988); 75: 800–803 Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics (1979); 6: 65–70. Hommel, G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika (1998); 75: 383–386. Lu. K, Graphical approaches using a Bonferroni mixture of weighted Simes test. Statistics in Medicine (2016); 35: 4041-4055 of 8 JSM2018